Developing a simulation tool to support decisions around the commissioning of anticoagulation services for patients with atrial fibrillation

Christos Vasilakis, Neophytos Stylianou

Research output: Contribution to conferenceAbstract

Abstract

Atrial fibrillation (AF), an arrhythmia characterized by chaotic electrical activity in the atria, is a public health problem affecting countries experiencing aging population ageing. AF not only increases the risk of stoke five-fold but a stroke suffered by this group of patients are more significant and result in more serious harm and greater mortality. Historically, Warfarin and aspirin have been the treatments of choice but recent guidance states that aspirin should not be used as a monotherapy. More recently a new class of drugs was developed, Novel Oral Anti-Coagulants (NOACs), which aim to treat AF while avoiding some of the drawbacks of Warfarin. However, each treatment comes with costs and benefits for both the patient and care system which need to be taken into account when planning the organisation of stroke prevention services at a regional or national level. Our aim was to develop a prototype modelling software tool to help with decisions around the organisation of anti-coagulation and stroke prevention services at regional level. Specifically, we constructed a stochastic simulation model representing patients with AF on different treatments and their respective outcomes. We implemented a prototype software tool to allow the execution of computer simulation experiments. Finally, we experimented with a number of showcasing scenarios that evaluate the likely impact of changes of in the mixture of medication treatments on patient and system level outcomes.

Conference

Conference29th European Conference on Operational Research (EURO2018)
CountrySpain
CityValencia
Period8/07/1811/07/18
Internet address

Fingerprint

Atrial Fibrillation
Stroke
Warfarin
Aspirin
Software
Organizations
Coagulants
Therapeutics
Computer Simulation
Cost-Benefit Analysis
Cardiac Arrhythmias
Patient Care
Public Health
Mortality
Pharmaceutical Preparations
Population

Cite this

Vasilakis, C., & Stylianou, N. (2018). Developing a simulation tool to support decisions around the commissioning of anticoagulation services for patients with atrial fibrillation. Abstract from 29th European Conference on Operational Research (EURO2018), Valencia, Spain.

Developing a simulation tool to support decisions around the commissioning of anticoagulation services for patients with atrial fibrillation. / Vasilakis, Christos; Stylianou, Neophytos.

2018. Abstract from 29th European Conference on Operational Research (EURO2018), Valencia, Spain.

Research output: Contribution to conferenceAbstract

Vasilakis, C & Stylianou, N 2018, 'Developing a simulation tool to support decisions around the commissioning of anticoagulation services for patients with atrial fibrillation' 29th European Conference on Operational Research (EURO2018), Valencia, Spain, 8/07/18 - 11/07/18, .
Vasilakis C, Stylianou N. Developing a simulation tool to support decisions around the commissioning of anticoagulation services for patients with atrial fibrillation. 2018. Abstract from 29th European Conference on Operational Research (EURO2018), Valencia, Spain.
Vasilakis, Christos ; Stylianou, Neophytos. / Developing a simulation tool to support decisions around the commissioning of anticoagulation services for patients with atrial fibrillation. Abstract from 29th European Conference on Operational Research (EURO2018), Valencia, Spain.
@conference{9711f9356688442a88c8a8eef48723a9,
title = "Developing a simulation tool to support decisions around the commissioning of anticoagulation services for patients with atrial fibrillation",
abstract = "Atrial fibrillation (AF), an arrhythmia characterized by chaotic electrical activity in the atria, is a public health problem affecting countries experiencing aging population ageing. AF not only increases the risk of stoke five-fold but a stroke suffered by this group of patients are more significant and result in more serious harm and greater mortality. Historically, Warfarin and aspirin have been the treatments of choice but recent guidance states that aspirin should not be used as a monotherapy. More recently a new class of drugs was developed, Novel Oral Anti-Coagulants (NOACs), which aim to treat AF while avoiding some of the drawbacks of Warfarin. However, each treatment comes with costs and benefits for both the patient and care system which need to be taken into account when planning the organisation of stroke prevention services at a regional or national level. Our aim was to develop a prototype modelling software tool to help with decisions around the organisation of anti-coagulation and stroke prevention services at regional level. Specifically, we constructed a stochastic simulation model representing patients with AF on different treatments and their respective outcomes. We implemented a prototype software tool to allow the execution of computer simulation experiments. Finally, we experimented with a number of showcasing scenarios that evaluate the likely impact of changes of in the mixture of medication treatments on patient and system level outcomes.",
author = "Christos Vasilakis and Neophytos Stylianou",
year = "2018",
language = "English",
note = "29th European Conference on Operational Research (EURO2018) ; Conference date: 08-07-2018 Through 11-07-2018",
url = "http://euro2018valencia.com",

}

TY - CONF

T1 - Developing a simulation tool to support decisions around the commissioning of anticoagulation services for patients with atrial fibrillation

AU - Vasilakis, Christos

AU - Stylianou, Neophytos

PY - 2018

Y1 - 2018

N2 - Atrial fibrillation (AF), an arrhythmia characterized by chaotic electrical activity in the atria, is a public health problem affecting countries experiencing aging population ageing. AF not only increases the risk of stoke five-fold but a stroke suffered by this group of patients are more significant and result in more serious harm and greater mortality. Historically, Warfarin and aspirin have been the treatments of choice but recent guidance states that aspirin should not be used as a monotherapy. More recently a new class of drugs was developed, Novel Oral Anti-Coagulants (NOACs), which aim to treat AF while avoiding some of the drawbacks of Warfarin. However, each treatment comes with costs and benefits for both the patient and care system which need to be taken into account when planning the organisation of stroke prevention services at a regional or national level. Our aim was to develop a prototype modelling software tool to help with decisions around the organisation of anti-coagulation and stroke prevention services at regional level. Specifically, we constructed a stochastic simulation model representing patients with AF on different treatments and their respective outcomes. We implemented a prototype software tool to allow the execution of computer simulation experiments. Finally, we experimented with a number of showcasing scenarios that evaluate the likely impact of changes of in the mixture of medication treatments on patient and system level outcomes.

AB - Atrial fibrillation (AF), an arrhythmia characterized by chaotic electrical activity in the atria, is a public health problem affecting countries experiencing aging population ageing. AF not only increases the risk of stoke five-fold but a stroke suffered by this group of patients are more significant and result in more serious harm and greater mortality. Historically, Warfarin and aspirin have been the treatments of choice but recent guidance states that aspirin should not be used as a monotherapy. More recently a new class of drugs was developed, Novel Oral Anti-Coagulants (NOACs), which aim to treat AF while avoiding some of the drawbacks of Warfarin. However, each treatment comes with costs and benefits for both the patient and care system which need to be taken into account when planning the organisation of stroke prevention services at a regional or national level. Our aim was to develop a prototype modelling software tool to help with decisions around the organisation of anti-coagulation and stroke prevention services at regional level. Specifically, we constructed a stochastic simulation model representing patients with AF on different treatments and their respective outcomes. We implemented a prototype software tool to allow the execution of computer simulation experiments. Finally, we experimented with a number of showcasing scenarios that evaluate the likely impact of changes of in the mixture of medication treatments on patient and system level outcomes.

M3 - Abstract

ER -